188
Views
0
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Non-Traditional Blood Lipid Indices for Metabolism Dysfunction-Associated Fatty Liver Disease Prediction in Non-Obese Type 2 Diabetes Mellitus

ORCID Icon, , ORCID Icon, ORCID Icon, ORCID Icon &
Pages 2345-2354 | Received 20 Apr 2023, Accepted 30 Jul 2023, Published online: 07 Aug 2023

References

  • Kuchay MS, Choudhary NS, Mishra SK. Pathophysiological mechanisms underlying MAFLD. Diabetes Metab Syndr. 2020;14(6):1875–1887. doi:10.1016/j.dsx.2020.09.026
  • Marchesini G, Day CP, Dufour JF, et al. EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64(6):1388–1402. doi:10.1016/j.jhep.2015.11.004
  • Rinella ME. Nonalcoholic fatty liver disease: a systematic review. JAMA. 2015;313(22):2263–2273. doi:10.1001/jama.2015.5370
  • Ali A, Amin MJ, Ahmed MU, Taj A, Aasim M, Tabrez E. Frequency of non-alcoholic fatty liver disease (NAFLD) and its associated risk factors among type-2 diabetics. Pak J Med Sci. 2022;38(1):28–33. PMID: 35035396; PMCID: PMC8713246. doi:10.12669/pjms.38.1.4968
  • Koo SY, Park EJ, Lee CW. Immunological distinctions between nonalcoholic steatohepatitis and hepatocellular carcinoma. Exp Mol Med. 2020;52(8):1209–1219. PMID: 32770081; PMCID: PMC8080649. doi:10.1038/s12276-020-0480-3
  • Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73(1):202–209. doi:10.1016/j.jhep.2020.03.039
  • Zheng KI, Fan JG, Shi JP, et al. From NAFLD to MAFLD: a “redefining” moment for fatty liver disease. Chin Med J. 2020;133(19):2271–2273. doi:10.1097/cm9.0000000000000981
  • Yano K, Seko Y, Takahashi A, et al. Effect of sodium glucose cotransporter 2 inhibitors on renal function in patients with nonalcoholic fatty liver disease and type 2 diabetes in Japan. Diagnostics. 2020;10(2):86. doi:10.3390/diagnostics10020086
  • Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15(1):11–20. doi:10.1038/nrgastro.2017.109
  • Wong VW, Wong GL, Woo J, et al. Impact of the new definition of metabolic associated fatty liver disease on the epidemiology of the disease. Clin Gastroenterol Hepatol. 2021;19(10):2161–2171.e5. doi:10.1016/j.cgh.2020.10.046
  • Zeng J, Qin L, Jin Q, et al. Prevalence and characteristics of MAFLD in Chinese adults aged 40 years or older: a community-based study. Hepatobiliary Pancreat Dis Int. 2022;21(2):154–161. doi:10.1016/j.hbpd.2022.01.006
  • Zhou X, Lin X, Chen J, et al. Clinical spectrum transition and prediction model of nonalcoholic fatty liver disease in children with obesity. Front Endocrinol. 2022;13:986841. PMID: 36120457; PMCID: PMC9471666. doi:10.3389/fendo.2022.986841
  • Zou Y, Zhong L, Hu C, Zhong M, Peng N, Sheng G. LDL/HDL cholesterol ratio is associated with new-onset NAFLD in Chinese non-obese people with normal lipids: a 5-year longitudinal cohort study. Lipids Health Dis. 2021;20(1):28. doi:10.1186/s12944-021-01457-1
  • Khamseh ME, Malek M, Abbasi R, Taheri H, Lahouti M, Alaei-Shahmiri F. Triglyceride glucose index and related parameters (triglyceride glucose-body mass index and triglyceride glucose-waist circumference) identify nonalcoholic fatty liver and liver fibrosis in individuals with overweight/obesity. Metab Syndr Relat Disord. 2021;19(3):167–173. doi:10.1089/met.2020.0109
  • Cui Y, Liu J, Shi H, Hu W, Song L, Zhao Q. Serum uric acid is positively associated with the prevalence of nonalcoholic fatty liver in non-obese type 2 diabetes patients in a Chinese population. J Diabetes Complications. 2021;35(5):107874. doi:10.1016/j.jdiacomp.2021.107874
  • Li N, Tan H, Xie A, et al. Value of the triglyceride glucose index combined with body mass index in identifying non-alcoholic fatty liver disease in patients with type 2 diabetes. BMC Endocr Disord. 2022;22(1):101. doi:10.1186/s12902-022-00993-w
  • Health Management Branch of the Chinese Medical Association CNBotCNS, Association. NaMBotNHIEM. Expert consensus on the weight management process for overweight or obese individuals. Chin J Health Manag. 2021;15(4):317–322.
  • Overweight/Obesity. ECWGoBQMPaPfCIPw. Expert consensus on body quality management pathways and processes for Chinese infertility patients with overweight/obesity. Chin J Reprod Contracept. 2020;40(12):965–971.
  • Babic N, Valjevac A, Zaciragic A, Avdagic N, Zukic S, Hasic S. The triglyceride/HDL ratio and triglyceride glucose index as predictors of glycemic control in patients with diabetes mellitus type 2. Med Arch. 2019;73(3):163–168. doi:10.5455/medarh.2019.73.163-168
  • Tarantino G, Crocetto F, Di Vito C, et al. Association of NAFLD and insulin resistance with non metastatic bladder cancer patients: a Cross-Sectional Retrospective Study. J Clin Med. 2021;10(2):346. PMID: 33477579; PMCID: PMC7831331. doi:10.3390/jcm10020346
  • Zeng J, Yang RX, Sun C, et al. Prevalence, clinical characteristics, risk factors, and indicators for lean Chinese adults with nonalcoholic fatty liver disease. World J Gastroenterol. 2020;26(15):1792–1804. doi:10.3748/wjg.v26.i15.1792
  • Zou ZY, Wong VW, Fan JG. Epidemiology of nonalcoholic fatty liver disease in non-obese populations: meta-analytic assessment of its prevalence, genetic, metabolic, and histological profiles. J Dig Dis. 2020;21(7):372–384. doi:10.1111/1751-2980.12871
  • Yoo JJ, Kim W, Kim MY, et al. Recent research trends and updates on nonalcoholic fatty liver disease. Clin Mol Hepatol. 2019;25(1):1–11. doi:10.3350/cmh.2018.0037
  • World Health Organization. Definition, Diagnosis and Classification of Diabetes Mellitus and Its Complications-Part 1: Diagnosis and Classification of Diabetes Mellitus. Geneva: World Health Organization; 1999.
  • Xing Y, Chen J, Liu J, Ma H. Associations between GGT/HDL and MAFLD: a Cross-Sectional Study. Diabetes Metab Syndr Obes. 2022;15:383–394. doi:10.2147/dmso.S342505
  • Eslam M, Sanyal AJ, George J. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020;158(7):1999–2014.e1. doi:10.1053/j.gastro.2019.11.312
  • Watt MJ, Miotto PM, De Nardo W, Montgomery MK. The liver as an endocrine organ-linking NAFLD and insulin resistance. Endocr Rev. 2019;40(5):1367–1393. doi:10.1210/er.2019-00034
  • Negi CK, Babica P, Bajard L, Bienertova-Vasku J, Tarantino G. Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease. Metabolism. 2022;126:154925. PMID: 34740573. doi:10.1016/j.metabol.2021.154925
  • Tarantino G, Balsano C, Santini SJ, et al. It is high time physicians thought of natural products for alleviating NAFLD. Is there sufficient evidence to use them? Int J Mol Sci. 2021;22(24):13424. PMID: 34948230; PMCID: PMC8706322. doi:10.3390/ijms222413424
  • Youssef ME, Yahya G, Popoviciu MS, Cavalu S, Abd-Eldayem MA, Saber S. Unlocking the full potential of SGLT2 inhibitors: expanding applications beyond glycemic control. Int J Mol Sci. 2023;24(7):6039. doi:10.3390/ijms24076039
  • Li L, Li Q, Huang W, et al. Dapagliflozin alleviates hepatic steatosis by restoring autophagy via the AMPK-mTOR pathway. Front Pharmacol. 2021;12:589273. PMID: 34093169; PMCID: PMC8176308. doi:10.3389/fphar.2021.589273
  • Kim JA, Hwang SY, Yu JH, et al. Association of the triglyceride and glucose index with low muscle mass: KNHANES 2008–2011. Sci Rep. 2021;11(1):450. doi:10.1038/s41598-020-80305-1
  • Luo E, Wang D, Yan G, et al. High triglyceride-glucose index is associated with poor prognosis in patients with acute ST-elevation myocardial infarction after percutaneous coronary intervention. Cardiovasc Diabetol. 2019;18(1):150. doi:10.1186/s12933-019-0957-3
  • Brody GH, Yu T, Chen E, Ehrlich KB, Miller GE. Racial discrimination, body mass index, and insulin resistance: a longitudinal analysis. Health Psychol. 2018;37(12):1107–1114. doi:10.1037/hea0000674
  • Malek M, Khamseh ME, Chehrehgosha H, Nobarani S, Alaei-Shahmiri F. Triglyceride glucose-waist to height ratio: a novel and effective marker for identifying hepatic steatosis in individuals with type 2 diabetes mellitus. Endocrine. 2021;74(3):538–545. doi:10.1007/s12020-021-02815-w
  • Pal SC, Méndez-Sánchez N. Screening for MAFLD: who, when and how? Ther Adv Endocrinol Metab. 2023;14:20420188221145650. doi:10.1177/20420188221145650
  • Ando Y, Jou JH. Nonalcoholic fatty liver disease and recent guideline updates. Clin Liver Dis. 2021;17(1):23–28. doi:10.1002/cld.1045
  • Mendez-Sanchez N, Arrese M, Gadano A, et al. The Latin American Association for the Study of the Liver (ALEH) position statement on the redefinition of fatty liver disease. Lancet Gastroenterol Hepatol. 2021;6(1):65–72. doi:10.1016/s2468-1253(20)30340-x
  • Méndez-Sánchez N, Bugianesi E, Gish RG, et al. Global multi-stakeholder endorsement of the MAFLD definition. Lancet Gastroenterol Hepatol. 2022;7(5):388–390. doi:10.1016/s2468-1253(22)00062-0
  • Yilmaz Y, Byrne CD, Musso G. A single-letter change in an acronym: signals, reasons, promises, challenges, and steps ahead for moving from NAFLD to MAFLD. Expert Rev Gastroenterol Hepatol. 2021;15(4):345–352. doi:10.1080/17474124.2021.1860019